Weiguang Biological Products to Invest 40 Million Yuan in Cell Therapy Platform Joint Venture
MT Newswires Live
Feb 05
Shenzhen Weiguang Biological Products (SHE:002880) plans to invest 40 million yuan into a joint venture that will set up a cell and gene therapy platform, according to a Thursday disclosure on the Shenzhen bourse.
The venture, Shenzhen Xihe Life Science, will build the Shenzhen cell and gene therapy market-oriented public service platform.
Xihe Life Science will have a registered capital of 100 million yuan, with the blood products manufacturer holding 40% of its equity.
The other investors and owners of the venture are Shenzhen Shenye Biomedical Industry Development, Shenzhen Cell Valley Biomedical and Shenzhen Saiqiao Bio-Innovation Technology.
The company's shares closed over 3% lower.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.